Document is current
Any future updates will be listed below
-
Authors
Kothari, G.
Hardcastle, N.
Perera, R.
Jackson, P.
Lee, S.
Silver, J. D.
Gaudreault, M.
Li, J.
Brown, C.
Mitchell, P. L. R.
Kron, T.
Welsh, J. W.
Theelen, W. S. M. E.
Siva, S.
-
Funding
Funding for this research was provided by:
Withers and Peters Grant, Royal Australian and New Zealand College of Radiologists
Cancer Council Victoria Colebatch Fellowship
- License Information
-
More Information
Article History
Received: 22 September 2025
Accepted: 12 May 2026
First Online: 28 May 2026
Declarations
:
: WSMET receives research funding to the NKI-AVL from MSD, AZ and Regeneron. JWW declares the following disclosures: Accuray (SAB, consulting), Alpine Immune Science (SAB, consulting, equity), Boehringer Ingelheim (SAB, consulting), Checkmate Pharmaceuticals (SAB, consulting, equity), China Medical Tribune (SAB, consulting), Genentech (SAB, consulting, Research grant), GI Innovation (SAB, consulting), Kezar Life Sciences (consulting, SAB), Legion Healthcare Partners (SAB, consulting), Life Science Dynamic Limited (SAB, consulting), McKesson Corporation (SAB, consulting), Molecular Match (equity), Nanorobotix (SAB, consulting), OligoImmune (founder), Roche (SAB, consulting), Roche Molecular Systems (SAB, consulting), Nanobiotix (Research grant, Travel expenses, SAB), BMS (Research grant), Merck (Research grant), Varian (Research grant, Travel expenses, clinical sponsored research), Reflexion (Research grant, Travel expenses, Stock options, SAB), Hotspot Therapeutics (Research grant), Gilead (Research grant), Novocure (SAB, Research grant), Oncoresponse (SAB, Stock options), Astra Zeneca (consultant, Research grant), Bayer Healthcare (Research grant), Kiromic (Research grant), Alkermes (Research grant, SAB), Artidis (Research grant), Sciclone (Research grant), Takeda (Research grant), Nurix (Research grant). All other authors have declared no conflicts of interest.
